Oncoinvent ASA
6.30
EUR
-0.14
(-2.17%)
ISIN
NO0013711713
Return %
Stock
S&P 500
1Y
-92.55
14.20
3Y
-94.83
81.12
5Y
-99.99
68.34
Capital Structure
NOK
•
in mil. unless spec.Working Capital
NOK
•
in mil. unless spec.Growth Rates
NOK
•
in mil. unless spec.Semi-annual Revenue
NOK
•
in mil. unless spec.Semi-annual Earnings Per Share
NOK
•
in mil. unless spec.Semi-annual Dividends Per Share
NOK
•
in mil. unless spec.Company Description
- CEO
- Øystein Soug
- Full Time Employees
- 44
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Gullhaugveien 7 Oslo PS Norway 0484
- IPO Date
- Apr 7, 2017
- Website
- oncoinvent.com
- Similar Companies
- Business
- Oncoinvent ASA, a Norwegian clinical-stage biotechnology company, specializes in radiopharmaceuticals designed for cancer care with a focus on alpha-emitting therapies for metastatic disease. The company develops Radspherin®, a lead product candidate consisting of an alpha-emitting radioactive microsphere suspension intended for intraperitoneal and body cavity treatment, along with radiotherapeutic and radioimmunotherapeutic programs targeting solid cancers. Oncoinvent operates primarily in Norway, with research, development, and clinical trial activities anchored in Oslo and related facilities, and maintains broader European engagement through partnerships and regulatory submissions. Founded in 2010, the company is headquartered in Oslo, Norway, and pursues growth through strategic collaborations, ongoing clinical trials, and potential expansion of its alpha-therapy platform across additional cancer indications and delivery modalities. Oncoinvent’s product portfolio emphasizes direct alpha radiation therapy, leveraging radionuclide technologies to deliver potent anticancer activity with targeted localization to tumor sites, aiming to offer new treatment options for patients with metastatic cancers. The company’s operations span research and development, manufacturing for clinical trial material, regulatory filings, and collaboration with academic and industry partners to advance its radiopharmaceutical pipeline. Oncoinvent maintains a focused mandate on improving cancer care through innovative radiopharmaceutical products, with an emphasis on safety, efficacy, and scalable manufacturing for clinical use. The firm prioritizes regulatory progress, strategic alliances, and potential licensing or co-development agreements to accelerate the clinical translation of its alpha-emitting therapies. Oncoinvent’s activities include preclinical studies, clinical development programs, and a pipeline centered on alpha-therapy platforms designed to address unmet medical needs in oncology. The company has positioned itself as a specialist in targeted radiopharmaceuticals, pursuing partnerships and funding opportunities to advance its lead asset and subsequent candidates through clinical development and potential commercialization. Oncoinvent’s ongoing initiatives reflect its commitment to transforming cancer treatment paradigms by delivering localized, high-precision radiopharmaceutical therapies to patients in Europe and beyond.